<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567876</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_V-RBAC</org_study_id>
    <nct_id>NCT03567876</nct_id>
  </id_info>
  <brief_title>Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL</brief_title>
  <official_title>Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, phase II trial designed to evaluate whether the addition of
      Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with
      mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free
      Survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to improve long term results of R-BAC, consolidating patients with
      high-risk (HR) features (defined as: elevated Ki67 and/or blastoid cytology and/or TP53
      mutation after central pathology review) with Venetoclax (ABT-199), which has demonstrated
      relevant single agent activity in relapsed/refractory MCL in a Phase 1-2 trial.

      The updated Progression Free Survival curves of the R-BAC500 trial has shown that the
      expected 2-years PFS for patients with HR disease is 40% (H0), as compared to low-risk
      patients (LR) that have a 2-years PFS of 100%. The addition of Venetoclax to HR patients
      after R-BAC is expected to improve results and efficacy of this regimen in this &quot;difficult
      -to- treat&quot; population, that represents approximately 40-45 % of newly diagnosed elderly
      patients with MCL. It appears reasonable to treat with the experimental drug also LR patients
      that do not respond appropriately (less than CR) at the end of R-BAC. Since the number of
      such LR patients is hardly predictable based on the present experience with R-BAC500 trial,
      the analysis of this sub-cohort will be of exploratory nature, and thus assessed separately.

      The study objective is to evaluate whether the addition of venetoclax after R-BAC to HR
      patients improves the results of the standard R-BAC, in terms of Progression Free Survival .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of the High Risk patients</measure>
    <time_frame>24 months</time_frame>
    <description>2-years progression-free survival (PFS) of the HR patients from date of enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response</measure>
    <time_frame>10 months and 30 months</time_frame>
    <description>The proportion of molecular response (analyzed in the labs of the FIL- MRD Network)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of all patients and different subgroups</measure>
    <time_frame>24 months</time_frame>
    <description>The progression-free survival (PFS) of all enrolled patients, and of different subgroups (i.e TP53 mutated patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>54 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of responses</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of complete remission in High Risk and Law Risk patients</measure>
    <time_frame>6 months and 10 months</time_frame>
    <description>The proportion of complete remission (CR) before and after venetoclax in the HR group and/or in the LR not responding to R-BAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completed expected treatment schedule</measure>
    <time_frame>30 months</time_frame>
    <description>The proportion of patients that complete the expected treatment schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>10 months and 30 months</time_frame>
    <description>The proportion of patients with adverse events as assessed by CTCAE 4.03 during venetoclax administration as consolidation or maintenance after R-BAC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>V-RBAC (RBAC followed by Venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction phase: RBAC --&gt; up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.
Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)</description>
    <arm_group_label>V-RBAC (RBAC followed by Venetoclax)</arm_group_label>
    <other_name>Venclyxto (commercial name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously untreated patients with MCL aged ≥65 years if they are FIT according to the
             geriatric CGA assessment.

          2. age ≤64 years not eliglible to high-dose chemotherapy plus transplantation at
             physician's judgement (details for non eligibility to be recorded by means of the
             CIRS, Cumulative Illness rating Scale).

          3. Measurable nodal or extranodal disease ≥ 1.5 cm in longest diameter, and measurable in
             2 perpendicular dimensions.

          4. ECOG performance status ≤2.

          5. Positivity for cyclin D1 and/or SOX11 [the latter being mandatory in cases lacking
             cyclin D1- or t(11;14)-negative].

          6. Adequate renal function (Creatinine clearance &gt;50 mL/min), with preserved diuresis.

          7. Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase
             (AST) &lt;2.5 x upper limit of normal (ULN) value, total bilirubin &lt;1.5 x ULN, unless
             directly attributable to the patient's tumor or to congenital causes.

          8. Hepatitis B core antibody (HBcAb) positive/HBsAg negative/HBV-DNA negative patients
             may be enrolled if correct antiviral prophylaxis is administered at least 2 weeks
             before initiating protocol treatment.

          9. Written informed consent.

        Exclusion Criteria:

          1. Human immunodeficiency virus (HIV) positive.

          2. Previous treatment for lymphoma.

          3. Disease confined to the bone marrow/peripheral blood/spleen, without any other nodal
             or extranodal involvement.

          4. In-situ MCL.

          5. Medical conditions or organ injuries that could interfere with administration of
             therapy.

          6. Active bacterial, viral, or fungal infection requiring systemic therapy.

          7. Seizure disorders requiring anticonvulsant therapy.

          8. Severe chronic obstructive pulmonary disease with hypoxiemia.

          9. History of severe cardiac disease: New York Heart Association (NYHA) functional class
             III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias,
             dilatative cardiomyopathy, or unstable angina.

         10. Uncontrolled diabetes mellitus.

         11. Active secondary malignancy.

         12. Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins, to
             Bendamustine or mannitol.

         13. Major surgery within 4 weeks of study Day 1.

         14. HBsAg+

         15. HCVAb+ patients with active viral replication (HCV-RNA+ with AST&gt;2 x normal limit)

         16. Any co-existing medical or psychological condition that would preclude participation
             in the study or compromise the patient's ability to give informed consent, or that may
             affect the interpretation of the results, or render the patient at high risk from
             treatment complications.

         17. CNS involvement

         18. Chronic treatment with strong or moderate CYP3A inhibitors (e.g. ketoconazole,
             ritonavir, clarithromycin, itraconazole, voriconazole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Visco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Integrata di Verona - U.O. Ematologia -Verona -Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Peracchio</last_name>
    <phone>00390131033154</phone>
    <email>cperacchio@filinf.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonella Ferranti</last_name>
    <phone>00390131033153</phone>
    <email>aferranti@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo, SC Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Ladetto</last_name>
      <email>marco.ladetto@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Marco Ladetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche, Clinica di Ematologia</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Gini</last_name>
      <email>guido.gini@ospedaliriuniti.marche.it</email>
    </contact>
    <investigator>
      <last_name>Guido Gini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico, S.O.C. Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II, UOC Ematologia</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giacomo Loseto</last_name>
      <email>loseto.giacomo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giacomo Loseto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi, Istituto di Ematologia &quot;Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani</last_name>
      <email>pierluigi.zinzani@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pier Luigi Zinzani, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale di Bolzano, Divisione di Ematologia e T.M.O.</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Mian</last_name>
      <email>michael.mian@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Michael Mian, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili, Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Re</last_name>
      <email>alessandro.re@asst-spedalicivili.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco, Ematologia</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giuseppina Cabras</last_name>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Maria Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Cosenza, UOC Ematologia</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Gentile</last_name>
      <email>massimogentile@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle, SC Ematologia</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Castellino</last_name>
      <email>castellino.c@ospedale.cuneo.it</email>
    </contact>
    <investigator>
      <last_name>Claudia Castellino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetta Puccini</last_name>
      <email>puccinib@aou-careggi.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Benedetta Puccini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Ballerini</last_name>
      <email>ballerini@unige.it</email>
    </contact>
    <investigator>
      <last_name>Marco Gobbi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Ematologia</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Giovanna Congiu</last_name>
      <email>angelagiovanna.congiu@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Angela Giovanna Congiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Ematologia</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Musuraca</last_name>
      <email>g.musuraca@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Ruggero Zilioli</last_name>
      <email>vittorioruggero.zilioli@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Ruggero Zilioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Corradini</last_name>
      <email>paolo.corradini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Corradini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Ferreri</last_name>
      <email>andres.ferreri@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Baldini</last_name>
      <email>luca.baldini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Luca Baldini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara, SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Nassi</last_name>
      <email>luca.nassi@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Luca Nassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Padova, Ematologia</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Piazza</last_name>
      <email>francesco.piazza@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Piazza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti</last_name>
      <email>k.patti@villasofia.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo, Divisione di Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Arcaini</last_name>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo Da Saliceto, UO Ematologia</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Arcari</last_name>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Croci, Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani</last_name>
      <email>monica.tani@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Stelitano</last_name>
      <email>caterinastelitano27@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli</last_name>
      <email>merli.francesco@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi, UO Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalia Molinari</last_name>
      <email>annalia.molinari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Annalia Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I - Università &quot;La Sapienza&quot;, Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Martelli</last_name>
      <email>martelli@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Martelli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica S. Cuore, Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Hohaus</last_name>
      <email>stefan.hohaus@Unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas, UO Ematologia</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro</last_name>
      <email>armando.santoro@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza, UO Ematologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Senese, UOC Ematologia</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Fabbri</last_name>
      <email>fabbri7@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Fabbri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Cavallo</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carola Boccomini</last_name>
      <email>cboccomini@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Carola Boccomini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello, SC Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piero Maria Stefani</last_name>
      <email>pmstefani@ulss.tv.it</email>
    </contact>
    <investigator>
      <last_name>Piero Maria Stefani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C. Panico, UOC Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine, Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Volpetti</last_name>
      <email>stefano.volpetti@asuiud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Volpetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo, UOC Ematologia</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Merli</last_name>
      <email>michelepavia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona, UO Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Visco</last_name>
      <email>carlovisco@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Visco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo, Divisione di Ematologia</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Chiara Tisi</last_name>
      <email>mariachiara.tisi@aulss8.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Maria Chiara Tisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>First line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

